Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
Status unconfirmed · Phase 1/Phase 2
Conditions studied: Solid Tumor, Adult
In brief
This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of Zotatifin (eFT226) in subjects with selected advanced solid tumor malignancies.
Key facts
- Study ID
- NCT04092673
- Run by
- Effector Therapeutics
- People needed
- 30
- Starts
- 2019-10-25
- Expected to finish
- 2025-03-31
- Last updated by the study team
- 2024-05-21
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Virginia Cancer Specialists — Fairfax, Virginia, United States (enrolling)
- Valkyrie Clinical Trials — Los Angeles, California, United States (enrolling)
- Memorial Sloan Kettering Cancer Center- Westchester — Harrison, New York, United States (enrolling)
- Memorial Sloan Kettering Cancer Center- David H. Koch Center for Cancer Care — New York, New York, United States (enrolling)
- MD Anderson Cancer Center — Houston, Texas, United States (enrolling)
- University of Southern California — Los Angeles, California, United States (enrolling)
- Stanford University — Palo Alto, California, United States (enrolling)
- START Midwest — Grand Rapids, Michigan, United States (enrolling)
- Memorial Sloan Kettering Cancer Center- Monmouth — Middletown, New Jersey, United States (enrolling)
- Memorial Sloan Kettering Cancer Center- Commack — Commack, New York, United States (enrolling)
- Hoag Memorial Hospital Presbyterian — Newport Beach, California, United States
- University of Toledo Medical Center — Toledo, Ohio, United States
- New Experimental Therapeutics of San Antonio - NEXT Oncology — San Antonio, Texas, United States
- Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.